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30-day Mortality in Patients with Early ST
Timing
of ST
Bivalirudin
(n¼2,889)
Heparin  GPI
(n¼2,911)
Relative risk
[95% CI] P-Value*
Acute (24
hrs)
1/36 (2.8%) 1/6 (16.7%) 0.17 [0.01,
2.16]
0.14
Subacute
(1-30d)
3/25 (12.0%) 15/34 (44.1%) 0.29 [0.10,
0.88]
0.01
Early
(30d)
4/60 (6.7%) 16/40 (40.0%) 0.19 [0.07,
0.52]
0.0002
*Cochran-Mantel-Haenszel c2 test stratiﬁed by study
Unadjusted population
p
PSM population
p
Bivalirudin
N ¼ 4370
UFH
N ¼
19,564
Bivalirudin
N ¼ 3649
UFH
N ¼
3649
% % % %
Death 0.3 1.0 <0.0001 0.3 0.7 0.01
Stroke 0.1 0.3 0.054 0.2 0.3 0.22
MI 0.6 1.2 0.0004 0.5 0.8 0.25
Amputation 1.3 4.5 <0.0001 1.5 2.0 0.09
Transfusion 3.4 10.0 <0.0001 4.0 5.3 0.009
MACE 2.2 6.6 <0.0001 2.3 3.5 0.003
NACE 5.4 14.8 <0.0001 5.9 7.9 0.0009
Association Between Activated Clotting Time (per 50 sec increase) and
Clinical Outcome
Unadjusted OR
(95% CI) p value
Adjusted OR
(95% CI)
p
value
In hospital overt
bleeding
0.94 (0.88, 1.01) 0.09 1.00 (0.93, 1.08) 0.96
In hospital death 0.79 (0.71, 0.88) <0.0001 1.01 (0.89, 1.15) 0.85
In hospital death/MI 0.98 (0.93, 1.04) 0.51 1.01 (0.95, 1.08) 0.77
1 year cardiac
death/MI
0.97 (0.93, 1.01) 0.16 1.00 (0.95, 1.04) 0.81
1 year cardiac
death/MI/TLR
0.97 (0.94, 1.00) 0.07 0.99 (0.96, 1.03) 0.57
Abbreviations: MI, myocardial infarction; TLR, target lesion revascularization
Models adjusted for age, sex, body mass index, hypertension, diabetes, heart failure, smoking,
cholesterol level, prior PCI/CABG, shock at presentation, MI at presentation, stent type (drug
eluting vs bare metal), glycoprotein IIb/IIIa use
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: This analysis from a very large US hospital database suggests that the
use of bivalirudin anticoagulation for PAI may confer signiﬁcant clinical beneﬁts over
heparin. These results require conﬁrmation in a prospective randomized trial.
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Background: Controversy exists regarding the optimal choice of anticoagulation
regimen for percutaneous coronary intervention (PCI). We performed a meta-analysis
of randomized controlled trials (RCT) to compare bivalirudin (bival) versus heparin
with provisional or routine glycoprotein IIb/IIIa inhibitor (GPI) use on 30-day out-
comes following PCI.
Methods: Medline/Pubmed and Cochrane CENTRAL were searched along with
recent abstract presentations at national meetings for all RCTs comparing BIV with
provisional GPI use versus heparin with provisional or routine GPI use for PCI.
Pooled estimates of 30 day outcomes were generated for with random-effect models to
compare the treatment groups. Data is presented as odds ratios (OR) [95% conﬁdence
intervals].
Results: Our analysis included 14 studies with 30,446 patients that were randomized
to either bivalirudin with provisional GPI use (n¼14,869) or heparin with provisional
GPI use (n¼6,451) or heparin with routine GPI use (n¼9,126). There was no sig-
niﬁcant difference between anticoagulation with bival compared with heparin for 30
day death (OR 0.94 [0.78-1.14]) or myocardial infarction (OR 1.11 [0.97-1.27]). Early
stent thrombosis was signiﬁcantly greater with bivalirudin compared with heparin (OR
1.62 [1.18-2.23], p¼0.003), especially when comparing bivalirudin versus heparin
with provisional GPI use (OR 2.09 [1.26-3.47], p¼0.005) or among STEMI patients
(OR 2.17 [1.15-4.10], p¼0.02). However, bivalirudin reduced the risk of major bleed
(OR 0.58 [0.49-0.69], p< 0.0001) and TIMI major bleeding (OR 0.58 [0.47-0.71], p<
0.0001) compared with heparin. Meta-regression analysis demonstrated that bleeding
risk with use of heparin signiﬁcantly increases with increasing GPI use (p¼0.02).
Conclusions: Meta-analysis of 14 RCTs with 30,446 patients demonstrated that
bivalirudin is associated with higher risk of stent thrombosis but lower risk of major
bleeding compared with heparin.
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Background: The risk of early (30 day) stent thrombosis (ST) is considerable after
primary PCI for STEMI. We sought to determine the independent predictors of early
ST and evaluate the risk of mortality after ST according to antithrombotic therapy
used during the index primary PCI.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhMethods: In a patient-level pooled analysis from the HORIZONS-AMI and EURO-
MAX trials, we studied 5,800 patients undergoing primary PCI at 188 sites, random-
ized to either bivalirudin or heparin a glycoprotein IIb/IIIa inhibitor (GPI). Predictors
of ST were determined by multivariate logistic regression, and 30-day mortality was
evaluated according to timing of ST and antithrombotic treatment received.
Results: Of 100 patients (1.7%) who developed early ST, 20 (20%) died within 30 days
of enrollment. By logistic regression, independent predictors of early ST were pre-PCI
TIMI grade ﬂow 0-1 and Killip class 2 at presentation. Bivalirudin was associated
with higher rates of early ST (2.1% vs. 1.4%, RR¼1.51, adj. p-value¼0.07) driven by a
higher incidence of acute ST (1.2% vs. 0.2%, RR¼6.04, p< 0.0001) with similar rates
of subacute ST (0.9% vs. 1.2%, RR¼0.74, p¼0.24) in comparison to heparin  GPI.
However, 30-day mortality rates among patients with ST were lower in the bivalirudin-
treated subset; this was consistent for both acute and subacute ST (Table). As a result,
only 4/2,889 bivalirudin-treated patients died within 30 days after early ST compared
to 16/2,911 heparin  GPI treated patients (0.14% vs. 0.56% respectively, P¼0.01).
Conclusions: Killip class 2 during acute MI presentation and pre-procedure TIMI
grade ﬂow 0-1 are independent predictors of early ST after primary PCI. Although the
risk of ST within 30 days is higher among patients treated with bivalirudin due to a
greater hazard of acute ST, death attributable to early ST is substantially less common
in patients having received bivalirudin compared to heparin  GPI.TCT-469
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Background: Monitoring the intensity of anticoagulation with heparin during
percutaneous coronary intervention (PCI) using the activated clotting time (ACT) is
one of the most frequently used tests in invasive cardiology. However, despite its
ubiquitous use, controversy remains regarding the association of ACT with ischemic
and bleeding events.
Methods: We reviewed all PCI procedures performed at Mayo Clinic (Rochester,
MN) between 2001 - 2012 and evaluated the association between the ACT value at the
time of PCI and in-hospital and 1-year outcomes. For descriptive purposes, ACT
values were grouped into tertiles. We used logistic and Cox proportional hazards
regression models to estimate the association of ACT, modeled continuously, with
outcomes while accounting for baseline characteristics.
Results: Of 12,059 patients studied, 3,978 (33.0%) had ACT < 227, 4,047 (33.6%) had
ACT227-285, and 4,034 (33.4%)hadACT>285.Groupswere similar regarding baseline
and procedural characteristics. In univariate analysis, ACT had associations with in-hos-
pital and 1-year clinical events; however, after multivariable adjustment, ACT at the time
of device activation was not independently associated with outcomes (Table).armacotherapy - Procedural Anticoagulants B137
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: ACT values were not independently associated with in-hospital
ischemic or bleeding events or 1-year cardiovascular events in a large population of
patients undergoing PCI.
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Background: In patients with ST-segment elevation myocardial infarction (STEMI)
undergoing primary percutaneous coronary intervention (PCI), unfractionated heparin
(UFH), low molecular weight heparin (LMWH), fondaparinux, or bivalirudin are
treatment options. The relative beneﬁts of each of these regimen merits more sys-
tematic investigation.
Methods: We conducted a Medline/EMBASE/CENTRAL search for randomized
trials (RCT) comparing parenteral antithrombotic therapies for patients undergoing
primary PCI. Five treatment groups were identiﬁed: UFH+Glycoprotein IIbIIIa
inhibitor (GPI), UFH, bivalirudin, fondaparinux or LMWH+GPI. The primary
ischemic outcome was short-term (in-hospital/30-days) major adverse cardiovas-
cular event (MACCE); the primary bleeding outcome was short-term major
bleeding.
Results: We identiﬁed 23 RCTs that enrolled 22899 patients. In the MTC models,
when compared with UFH+GPI, UFH (OR¼1.48; 95% CI 1.18-1.86), bivalirudin
or fondaparinux (numerically higher) were associated with higher MACCE.
Similarly, when compared with LMWH+GPI, UFH (OR¼2.63; 95% CI 1.28-5.26),
bivalirudin (OR¼2.27; 95% CI 1.09-4.76) and fondaparinux (OR¼3.12; 95% CI
1.27-7.69) were associated with a higher MACCE. LMWH+GPI, followed by
UFH+GPI, bivalirudin, UFH and fondaparinux were the hierarchy for treatment
efﬁcacy for MACCE (highest to lowest rank). For bleeding, when compared with
UFH+GPI, both UFH (OR¼0.70; 95% CI 0.55-0.89) and bivalirudin (OR¼0.61;
95% CI 0.47-0.79) were associated with lower major bleeding. Bivalirudin, fol-
lowed by UFH, LMWH+GPI, UFH+GPI and fondaparinux were the hierarchy for
treatment safety (highest to lowest rank). Results were similar in direct comparison
meta-analyses: bivalirudin was associated with a 37% increase in MI, 44% increase
in urgent revascularization, and an 81% increase in stent thrombosis when
compared with UFH or UFH+GPI but with a 43% decrease in major bleeding
when compared with UFH+GPI with no difference when compared with UFH
alone.
Conclusions: In patients undergoing primary PCI, UFH+GPI and LMWH+GPI were
most efﬁcacious with the lowest MACCE rate, whereas bivalirudin was safest with the
lowest bleeding.
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Background: The use of anticoagulants in the setting of acute myocardial infarction
can lead to improvement of short-term survival by costing the increase of bleeding
risk. We performed a meta-analysis of all randomized data that has evaluated the
clinical outcomes among those patients admitted for acute STEMI and that received
either heparin or bivalirudin.
Methods: Pub Med, Chocrane and Scopus were systematically searched up to May
2014. Subjects of analysis were 30 days mortality, AMI, Target Lesion Revascular-
ization, major revascularization, and in-stent thrombosis. We used Fixed or Random
Effect analysis using the Cochrane Handbook of Systematic Reviews.
Results: A total of 3 studies provided a total of 7629 patients, being 3804 in the
bivalirudin group and 3825 patients in the heparin group. There was a strong trend
(p¼0.11) towards decreased AMI in the heparin group, with associated signiﬁcant
decrease of TLR and in-stent thrombosis (p< 0.05). Major bleeding trended towards
the heparin group (Figure 1).
Conclusions: Our analysis suggests that heparin might be associated with better
outcomes at post STEMI event, although there was no mortality beneﬁt. Some of
those beneﬁts might be due to decreased in stent thrombosis. Therefore large ran-
domized studies are warranted.B138 JACC Vol 64/11/Suppl B j SeptemberPharmacotherapy - GPIIb/IIIa inhibitors
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Background: Excess dosing of antithrombotic agents has been associated with
adverse outcomes. To date, dosing errors have not been studied in pts speciﬁcally
undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes
(ACS).
Methods: Analysis was performed in pts who received recommended (labeled
dosing) vs. excess eptiﬁbatide bolus or infusion doses during PCI in the HORI-
ZONS-AMI and ACUITY trials. Adverse outcome rates were assessed. Multivar-
iable analysis was performed to determine predictors of excess dosing and adverse
events.
Results: Of 5,287 pts (840 STEMI, 4,447 NSTEACS) treated with eptiﬁbatide, 543
(10.3%) were administered doses outside the recommended range (including in 319
of 574 pts (56%) with renal dysfunction [creatinine clearance < 50 mL/min].
Predictors of excess dosing included STEMI presentation, baseline creatinine
clearance, baseline hematocrit, and hypertension. Pts who received excess dosing
experienced higher rates of adverse outcomes (Table). By multivariable analysis,
excess dosing was independently associated with 30-day non-CABG major bleeding
(HR [95%CI] ¼ 1.38 [1.05, 1.82], p¼0.02) but not 30-day or 1-year all-cause
mortality (HR [95%CI] ¼ 1.47 [0.79, 2.74], p¼0.22, and 1.26 [0.84, 1.88], p¼0.27,
respectively].
Conclusions: In this large-scale study, excess dosing of eptiﬁbatide during PCI
for ACS was common (even in the clinical trial setting), and was an inde-
pendent predictor of major bleeding but not early or late mortality. Quality
control efforts to ensure proper dosing may improve outcomes in high-risk
ACS pts.13–17, 2014 j TCT Abstracts/Pharmacotherapy - GPIIb/IIIa inhibitors
